- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT04876053
Házhoz szállítás a cukorbetegség kezelésére vidéki klinikák betegei számára
Hosszú távú célunk a vidékiek T2DM irányításának átalakítása. Ennek a tanulmánynak az a célja, hogy meghatározza egy olyan beavatkozás hatékonyságát, amely méretezhető és fenntartható, és elősegíti a betegek adherenciáját azáltal, hogy enyhíti a vidéki élelmiszer-bizonytalanságban szenvedő résztvevők nehézségeit, amelyek a meglévő beavatkozások befejezésével kapcsolatosak. Konkrét céljaink a következők:
- Hasonlítsa össze a Healthy Food Delivery Intervention (HFDI) és a standard ellátás hatékonyságát önmagában, hogy javítsa a cukorbetegséggel összefüggő kimeneteleket a T2DM-ben szenvedő vidéki, élelmiszer-bizonytalanságban szenvedő betegek körében. Hipotézis: Összehasonlítva a standard ellátással, a HFDI plusz standard ellátásban részesülő betegek javult: H1 glikémiás kontroll a HbA1c-vel mérve; H2 kardio-metabolikus kockázati tényezők: vérnyomás, éhomi glükóz, éhgyomri lipidek és BMI; H3 önmenedzselés: énhatékonyság, önmenedzselési magatartásokhoz való ragaszkodás és gyógyszeradherencia; H4 betegközpontú eredmények: cukorbetegséggel összefüggő szorongás, cukorbetegséggel összefüggő életminőség és cukorbetegséggel összefüggő szövődmények.
- Hasonlítsa össze a HFDI plusz standard ellátás és önmagában a standard ellátás hatékonyságát, hogy javítsa az étrend minőségét a T2DM-ben szenvedő vidéki, élelmiszer-bizonytalanságban szenvedő betegek körében. Hipotézis: Összehasonlítva a standard ellátással, a HFDI plusz standard ellátásban részesülő betegek javultak: H1 Healthy Eating Index 2015 (HEI-2015) pontszámok; H2 gyümölcs és zöldség fogyasztás.
- Hasonlítsa össze a költséghatékonyságot, hogy megértse a HFDI plusz standard ellátási költségeket az egyedüli standard ellátás eredményeihez viszonyítva. Hipotézis: A HFDI költséghatékony lesz a hagyományos költségek alapján, minden további, minőséggel kiigazított élettartamra vetítve.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.
This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.
The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.
Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.
Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.
Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.
Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.
Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.
Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.
Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 12 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Arkansas
-
Batesville, Arkansas, Egyesült Államok, 72501
- UAMS - North Central
-
Corning, Arkansas, Egyesült Államok, 72422
- Pocahontas Medical Center
-
Eureka Springs, Arkansas, Egyesült Államok, 72632
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Egyesült Államok, 72703
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Egyesült Államok, 72703
- UAMS - Northwest
-
Fort Smith, Arkansas, Egyesült Államok, 72901
- UAMS - West
-
Harrison, Arkansas, Egyesült Államok, 72601
- Washington Regional Medical Center
-
Helena, Arkansas, Egyesült Államok, 72390
- UAMS - East
-
Jonesboro, Arkansas, Egyesült Államok, 72401
- UAMS - Northeast
-
Magnolia, Arkansas, Egyesült Államok, 71753
- UAMS - South
-
Marianna, Arkansas, Egyesült Államok, 72360
- Lee County Cooperative Clinic
-
Marshall, Arkansas, Egyesült Államok, 72650
- Boston Mountain Rural Health Center
-
Pocahontas, Arkansas, Egyesült Államok, 72455
- Pocahontas Medical Clinic
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Leírás
Bevételi kritériumok:
- 18 éves vagy idősebb
- élelmiszer-bizonytalanságot jelenteni
- jelentés T2D (megerősíti, hogy a HbA1c 6,5 vagy annál nagyobb a kezdeti adatgyűjtéskor, közvetlenül a hozzájárulást követően)
- Beszéljen angolul vagy spanyolul
- Jelenleg vidéki lakcímen él
Kizárási kritériumok:
- olyan körülmények, amelyek valószínűtlenné teszik, hogy a résztvevő képes lesz követni a protokollt, például halálos betegség, súlyos mentális betegség, súlyos látás- vagy halláskárosodás, étkezési zavar vagy a földrajzi régióból való kiköltözés terve
- Terhes
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Támogató gondoskodás
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Aktív összehasonlító: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
|
Kísérleti: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
|
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food.
Food boxes were designed by a Registered Dietician.
Food boxes also included recipes and cooking tips specific to foods included in that week's box.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Hemoglobin A1c (HbA1c)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Diet Quality: Healthy Eating Index-2015 Score
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks)
|
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software.
The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations.
HEI-2015 consists of 13 individual components.
HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
|
Baseline; Immediate post-intervention (approx. 12 weeks)
|
|
Diet Quality: Veggie Meter Score
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy.
The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption.
Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis.
Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Body Mass Index (BMI)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale.
Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Systolic Blood Pressure (SBP)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diastolic Blood Pressure (DBP)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Total Cholesterol
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
High-Density Lipoproteins (HDL)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Low-Density Lipoproteins (LDL)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Triglycerides
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Glucose
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diabetes Self-Efficacy (DMSES)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes.
The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes.
The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diabetes-Related Distress (PAID-5)
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress.
The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed.
Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Food Insecurity
Időkeret: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Food insecurity was assessed using the 2-item Hunger Vital Sign.
Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity.
Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Nyomozók
- Kutatásvezető: Pearl A McElfish, PhD, University of Arkansas
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 261074
- 5R01NR019487 (Az Egyesült Államok NIH támogatása/szerződése)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .